We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and intellectual disabilities. The “mGluR theory of fragile X” proposed by MIT Professor Mark Bear and collaborators in 2004 is widely considered to be a key conceptual breakthrough, and laid the foundation for development of disease-modifying therapies for treatment of Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to develop and market the first approved therapy in Fragile X Syndrome.
The name Allos Pharma is derived from
allistic, meaning not autistic.
Company Details
- Founded
- -
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.allospharma.com
- Keywords
- Copenhagen.
Allos Pharma Questions
Allos Pharma's website is http://www.allospharma.com
Allos Pharma's LinkedIn profile is https://www.linkedin.com/company/allos-pharma
Allos Pharma's industry is
Pharmaceutical Manufacturing
Allos Pharma's top competitors are
Hawaii Biotech, Inc.,
Cathvision,
Komo Biosciences,
Cyanotech Corporation,
Pacific Biotech Sas,
Moana Technologies Llc,
Findzebra,
Cardax, Inc.,
Allos,
Antag Therapeutics.
Allos Pharma's categories are Pharmaceutical Manufacturing
Allos Pharma's founding year is 2020
